In this video, Associate Professor Piers Blombery explores the biology of IGHV, somatic hypermutation, and their role in the pathogenesis of CLL. He discusses the clinical utility of IGHV testing, outlining its role in prognosis and treatment decision-making. The video also covers practical aspects of IGHV testing, including sample requirements, testing methodology using next-generation sequencing, and testing access in Australia.

This video is part of a two-part series in which experts discuss the role of IGHV testing in frontline CLL management.

This video was created independently by the limbic. All content was developed by the presenters and views are those of the presenters alone.

Thank you to AstraZeneca for providing the unrestricted educational grant that made this project possible.